GC Biopharma’s Barycela Secures First Marketing Approval in Latin America

Industry Insights from Next Move Strategy Consulting

GC Biopharma has achieved a significant milestone in the Biotechnology Market with its varicella vaccine, Barycela, receiving marketing authorization from the Guatemalan Ministry of Public Health and Social Assistance (Ministerio de Salud Pública y Asistencia Social). This marks the first time Barycela has been approved in a Latin American country, signaling the company’s growing presence in the region.

Expanding Access Through Innovative Vaccine Technology

Barycela, a live vaccine developed using GC Biopharma’s proprietary "MAV/06" strain, is recognized as the world’s first varicella vaccine manufactured without antibiotics. This innovation eliminates risks associated with antibiotic residues, such as kanamycin, neomycin, and erythromycin, enhancing product safety while maintaining high immunogenicity. Long-term clinical follow-up indicates that neutralizing antibodies are generated in 99–100% of recipients, with antibody persistence comparable to leading global vaccines.

With existing distribution through the Pan American Health Organization (PAHO), GC Biopharma plans to accelerate expansion into individual Latin American countries, leveraging this regulatory approval to broaden access and adoption. Following its inclusion in the WHO Position Paper, Barycela now holds international recognition equivalent to Oka-strain-based vaccines and can be used interchangeably with these global products.

“This marketing authorization holds deep significance as it marks our first product approval in Latin America,” said Lee Jae-woo, Head of the Development Division at GC Biopharma. “We will strengthen Barycela’s global standing based on its differentiated product capabilities and remain committed to expanding access to our innovative therapies worldwide.”

According to Next Move Strategy Consulting

The approval of Barycela in Guatemala demonstrates a growing trend of biotechnology companies advancing region-specific vaccine access while leveraging antibiotic-free formulations to enhance safety and efficacy. Analysts expect this development to drive increased adoption of GC Biopharma’s innovative vaccines in Latin America, positioning the company competitively in the global varicella vaccine market.

Source: The Pharma Letter

Prepared By: Next Move Strategy Consulting

About the Author

Sanyukta Deb — Sanyukta Deb is Digital Marketing Team Lead at Next Move Strategy Consulting, where she has led content strategy and technical SEO for the firm's B2B market research publications for over 2 years. Her editorial process translates NextMSC's primary and secondary research — spanning technology, industrial, and consumer sectors — into commercial narratives, backed by search-intent, keyword, and competitive analysis. She brings 5 years of overall experience in digital marketing and content strategy.

About the Reviewer

Debashree Dey — Debashree Dey is Assistant Manager at Next Move Strategy Consulting, where she supports cross-vertical market content and communications across diverse industries for 6 years. Her professional background includes senior content writing, communications, and published manuscript authorship, with experience developing audience-focused business narratives and maintaining clear, consistent messaging. Her role supports research-led content development and editorial quality across NextMSC publications.